Scholar Rock Holding Corporation participated in the 44th Annual J.P. Morgan Healthcare Conference, presenting a corporate update on January 12, 2026. The company’s management discussed recent advancements, including progress on regulatory approvals and commercialization plans for apitegromab in spinal muscular atrophy (SMA), expansion of manufacturing capacity with a second U.S. fill-finish facility, and ongoing clinical development of SRK-439. The presentation was webcast live and made available for replay on the Scholar Rock website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scholar Rock Holding Corporation published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.